Tarsons Products Limited (TARSONS) — Financial Results

· NSE 🔴 High Importance Neutral

Tarsons Products Limited reported consolidated revenue of ₹422.5 crores for FY26, reflecting an 8% YoY growth, driven by domestic demand and new capacity utilization, though PAT declined due to depreciation and finance costs from new facilities. Exports fell 13% in Q4FY26 amid Middle East geopolitical disruptions, while adjusted cash PAT grew 21% YoY to ₹112 crores. The company emphasized full commissioning of Panchla and Amta facilities by H1FY27 to accelerate growth.

📄 View Original Announcement (PDF)

About Tarsons Products Limited (TARSONS)

Healthcare · Healthcare Equipment & Supplies · Listed on NSE

Market Cap: ₹1,101.1 Cr P/E: 36.9

View full TARSONS stock details →

📡 Get AI alerts when TARSONS files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track TARSONS — Free

📊 More TARSONS filings

See all TARSONS filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

📡 Get AI alerts when TARSONS files new disclosures

Track TARSONS filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track TARSONS — Free

Free account · 2 AI queries/day